Current Problems in Cancer
Volume 32, Issue 5 , Pages 187-235 , September 2008

DNA Methylation: Its Role in Cancer Development and Therapy

  • C. Kurkjian, MD

      Affiliations

    • Fellow, Advanced Developmental Therapeutics Training Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland
    • ,
  • S. Kummar, MD

      Affiliations

    • Senior Staff Clinician, Medical Oncology Branch, Center for Clinical Research, National Cancer Institute, Bethesda, Maryland
    • ,
  • A.J. Murgo, MD, MS

      Affiliations

    • Head of Early Clinical Trials Development, NCI Division of Treatment and Diagnosis, Adjunct Investigator and Head of the Developmental Therapeutics Section, Center for Cancer Research, Medical Oncology Branch, Adjunct Professor of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland

References 

  1. Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 2001;61:3573–3577
  2. Henderson JP, Byun J, Williams MV, McCormick ML, Parks WC, Ridnour LA, et al. Bromination of deoxycytidine by eosinophil peroxidase: a mechanism for mutagenesis by oxidative damage of nucleotide precursors. Proc Natl Acad Sci U S A. 2001;98:1631–1636
  3. Whiteman M, Jenner A, Halliwell B. Hypochlorous acid-induced base modifications in isolated calf thymus DNA. Chem Res Toxicol. 1997;10:1240–1246
  4. Valinluck V, Sowers LC. Inflammation-mediated cytosine damage: a mechanistic link between inflammation and the epigenetic alterations in human cancers. Cancer Res. 2007;67:5583–5586
  5. Forman D, Newell DG, Fullerton F, Yarnell JW, Stacey AR, Wald N, et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. Br Med J. 1991;302:1302–1305
  6. Hansen S, Melby KK, Aase S, Jellum E, Vollset SE. Helicobacter pylori infection and risk of cardia cancer and non-cardia gastric cancer (A nested case-control study). Scand J Gastroenterol. 1999;34:353–360
  7. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez-Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991;325:1132–1136
  8. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127–1131
  9. Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res. 2006;12:989–995
  10. Fuccio L, Zagari RM, Minardi ME, Bazzoli F. Systematic review: Helicobacter pylori eradication for the prevention of gastric cancer. Aliment Pharmacol Ther. 2007;25:133–141
  11. Moayyedi P, Wason C, Peacock R, Walan A, Bardhan K, Axon AT, et al. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter. 2000;5:206–214
  12. Zerbib F, Lenk C, Sawan B, Cayla R, Broutet N, Carles B, et al. Long-term effects of Helicobacter pylori eradication on gastric antral mucosa in duodenal ulcer patients. Eur J Gastroenterol Hepatol. 2000;12:719–725
  13. Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer. 2007;7:599–612
  14. Martinez-Chantar ML, Garcia-Trevijano ER, Latasa MU, Perez-Mato I, Sanchez del Pino MM, Corrales FJ, et al. Importance of a deficiency in S-adenosyl-L-methionine synthesis in the pathogenesis of liver injury. Am J Clin Nutr. 2002;76:1177S–1182S
  15. Giovannucci E, Rimm EB, Ascherio A, Stampfer MJ, Colditz GA, Willett WC. Alcohol, low-methionine–low-folate diets, and risk of colon cancer in men. J Natl Cancer Inst. 1995;87:265–273
  16. Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. J Am Med Assoc. 2007;297:2351–2359
  17. Nakagawa H, Nuovo GJ, Zervos EE, Martin EW, Salovaara R, Aaltonen LA, et al. Age-related hypermethylation of the 5′ region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res. 2001;61:6991–6995
  18. Albitar M, Manshouri T, Shen Y, Liu D, Beran M, Kantarjiran HM, et al. Myelodysplastic syndrome is not merely “preleukemia.. ” Blood. 2002;100:791–798
  19. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109:1536–1542
  20. Lai F, Godley LA, Joslin J, Fernald AA, Liu J, Espinosa R, et al. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). Genomics. 2001;71:235–245
  21. Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Blough RR, et al. Clinical and cytogenetic correlations in 63 patients with therapy- related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol. 1986;4:325–345
  22. Boumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, Konishi K, et al. RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res. 2007;67:1997–2005
  23. Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C, Bauters F, et al. Methylation of the p15INK4b gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood. 1998;91:2985–2990
  24. Tien H-F, Tang J-L, Tsay W, Liu M-C, Lee F-Y, Wang C-H, et al. Methylation of the p15INK4B gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol. 2001;112:148–154
  25. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A. 1996;93:9821–9826
  26. Herman JG, Civin CI, Issa J-PJ, Collector MI, Sharkis SJ, Baylin SB. Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res. 1997;57:837–841
  27. Melki JR, Vincent PC, Clark SJ. Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res. 1999;59:3730–3740
  28. Issa J-PJ, Zehnbauer BA, Civin CI, Collector MI, Sharkis SJ, Davidson NE, et al. The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res. 1996;56:973–977
  29. Liu Z-J, Zhang X-B, Zhang Y, Yang X. Progesterone receptor gene inactivation and CpG island hypermethylation in human leukemia cancer cells. FEBS Lett. 2004;567:327–332
  30. Scardocci A, Guidi F, D'Alo F, Gumiero D, Fabiani E, Diruscio A, et al. Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia. Br J Cancer. 2006;95:1108–1113
  31. Furukawa Y, Sutheesophon K, Wada T, Nishimura M, Saito Y, Ishii H, et al. Methylation silencing of the Apaf-1 gene in acute leukemia. Mol Cancer Res. 2005;3:325–334
  32. Ponder BAJ. Cancer genetics. Nature. 2001;411:336–341
  33. Garcia-Manero G, Daniel J, Smith TL, Kornblau SM, Lee M-S, Kantarjian HM, et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res. 2002;8:2217–2224
  34. Corn PG, Smith BD, Ruckdeschel ES, Douglas D, Baylin SB, Herman JG. E-Cadherin expression is silenced by 5′ CpG island methylation in acute leukemia. Clin Cancer Res. 2000;6:4243–4248
  35. Roman-Gomez J, Jimenez-Velasco A, Barrios M, Prosper F, Heiniger A, Torres A, et al. Poor prognosis in acute lymphoblastic leukemia may relate to promoter hypermethylation of cancer-related genes. Leuk Lymphoma. 2007;48:1269–1282
  36. Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Agirre X, Barrios M, Navarro S, et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood. 2004;104:2492–2498
  37. Taylor KH, Pena-Hernandez KE, Davis JW, Arthur GL, Duff DJ, Shi H, et al. Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res. 2007;67:2617–2625
  38. Kusy S, Cividin M, Sorel N, Brizard F, Guilhot F, Brizard A, et al. p14ARF, p15INK4b, and p16INK4a methylation status in chronic myelogenous leukemia. Blood. 2003;101:374–375
  39. Zion M, Ben-Yehuda D, Avraham A, Cohen O, Wetzler M, Melloul D, et al. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc Natl Acad Sci U S A. 1994;91:10722–10726
  40. Asimakopoulos FA, Shteper PJ, Krichevsky S, Fibach E, Polliack A, Rachmilewitz E, et al. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood. 1999;94:2452–2460
  41. Issa JP, Kantarjian H, Mohan A, O'Brien S, Cortes J, Pierce S, et al. Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood. 1999;93:2075–2080
  42. Nguyen TT, Mohrbacher AF, Tsai YC, Groffen J, Heisterkamp N, Nichols PW, et al. Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications. Blood. 2000;95:2990–2992
  43. Melki JR, Vincent PC, Brown RD, Clark SJ. Hypermethylation of E-cadherin in leukemia. Blood. 2000;95:3208–3213
  44. Crossen PE, Morrison MJ. Hypermethylation of the M27beta (DXS255) locus in chronic B-cell leukaemia. Br J Haematol. 1998;100:191–193
  45. Rush LJ, Plass C. Restriction landmark genomic scanning for DNA methylation in cancer: past, present, and future applications. Anal Biochem. 2002;307:191–201
  46. Rush LJ, Raval A, Funchain P, Johnson AJ, Smith L, Lucas DM, et al. Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res. 2004;64:2424–2433
  47. Liu T-H, Raval A, Chen S-S, Matkovic JJ, Byrd JC, Plass C. CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Res. 2006;66:653–658
  48. Aaltonen LA, Peltomaki P, Leach FS, Sistonen P, Pylkkanen L, Mecklin JP, et al. Clues to the pathogenesis of familial colorectal cancer. Science. 1993;260:812–816
  49. Thibodeau SN, Bren G, Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 1993;260:816–819
  50. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa J-PJ, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998;95:6870–6875
  51. Bettstetter M, Dechant S, Ruemmele P, Grabowski M, Keller G, Holinski-Feder E, et al. Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR. Clin Cancer Res. 2007;13:3221–3228
  52. Watanabe T, Kobunai T, Toda E, Yamamoto Y, Kanazawa T, Kazama Y, et al. Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are different from proximal MSI cancers. Cancer Res. 2006;66:9804–9808
  53. Wang YC, Lu YP, Tseng RC, Lin RK, Chang JW, Chen JT, et al. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J Clin Invest. 2003;111:887–895
  54. Xinarianos G, Liloglou T, Prime W, Maloney P, Callaghan J, Fielding P, et al. hMLH1 and hMSH2 expression correlates with allelic imbalance on chromosome 3p in non-small cell lung carcinomas. Cancer Res. 2000;60:4216–4221
  55. Hsu H-S, Wen C-K, Tang Y-A, Lin R-K, Li W-Y, Hsa W-H, et al. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer. Clin Cancer Res. 2005;11:5410–5416
  56. Strathdee G, MacKean MJ, Illand M, Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene. 1999;18:2335–2341
  57. Gifford G, Paul J, Vasey PA, Kaye SB, Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res. 2004;10:4420–4426
  58. Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, et al. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res. 2005;65:10692–10699
  59. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 2000;60:5329–5333
  60. Wilcox CB, Baysal BE, Gallion HH, Strange MA, DeLoia JA. High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet. 2005;159:114–122
  61. Wang C, Horiuchi A, Imai T, Ohira S, Itoh K, Nikaido T, et al. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene. J Pathol. 2004;202:215–223
  62. Seng TJ, Currey N, Cooper WA, Lee CS, Chan C, Horvath L, et al. DLEC1 and MLH1 promoter methylation are associated with poor prognosis in non-small cell lung carcinoma. Br J Cancer. 2008;99:375–382
  63. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med. 2008;358:1118–1128
  64. Gu J, Berman D, Lu C, et al. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Clin Cancer Res. 2006;12:7329–7338
  65. Kim D-H, Nelson HH, Wiencke JK, Zheng S, Christiani DC, Wain JC, et al. p16INK4a and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res. 2001;61:3419–3424
  66. Russo AL, Thiagalingam A, Pan H, Califano J, Cheng K-H, Ponte JF, et al. Differential DNA hypermethylation of critical genes mediates the stage-specific tobacco smoke-induced neoplastic progression of lung cancer. Clin Cancer Res. 2005;11:2466–2470
  67. Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005;365:1769–1778
  68. Johnson-Maddux A, Ashfaq R, Cler L, Naftalis E, Leitch AM, Hoover S, et al. Reproducibility of cytologic atypia in repeat nipple duct lavage. Cancer. 2005;103:1129–1136
  69. Suijkerbuijk KPM, van der Wall E, Vooijs M, van Diest PJ. Molecular analysis of nipple fluid for breast cancer screening. Pathobiology. 2008;75:149–152
  70. Belinsky SA, Liechty KC, Gentry FD, Wolf HJ, Rogers J, Vu K, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res. 2006;66:3338–3344
  71. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res. 2000;60:5954–5958
  72. Zhang Y-J, Wu H-C, Shen J, Ahsan H, Tsai WY, Yang H-I, et al. Predicting hepatocellular carcinoma by detection of aberrant promoter methylation in serum DNA. Clin Cancer Res. 2007;13:2378–2384
  73. Stupp R, Mason WP , van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N Engl J Med. 2005;352:987–996
  74. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003
  75. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26:2192–2197
  76. Levin B, Lieberman DA, McFarland B, Smith RA, Brooks D, Andrews KS, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58:130–160
  77. Huang ZH, Li LH, Yang F, Wang JF. Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J Gastroenterol. 2007;13:950–954
  78. Lecomte T, Berger A, Zinzindohoue F, Micard S, Landi B, Blons H, et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer. 2002;100:542–548
  79. Ito S, Nakayama H, Kodera Y, Ito K, Akiyama S, Nakao A. Detection of tumor DNA in serum of colorectal cancer patients. Jpn J Cancer Res. 2002;93:1266–1269
  80. Zou H-Z, Yu B-M, Wang Z-W, Sun J-Y, Cang H, Gao F, et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin Cancer Res. 2002;8:188–191
  81. Nakayama H, Hibi K, Takase T, Yamazaki T, Kasai Y, Ito K, et al. Molecular detection of p16 promoter methylation in the serum of recurrent colorectal cancer patients. Int J Cancer. 2003;105:491–493
  82. Aggerholm A, Holm MS, Guldberg P, Olesen LH, Hokland P. Promoter hypermethylation of p15INK4B (HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients). Eur J Haematol. 2006;76:23–32
  83. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794–1803
  84. Ganser AHG, Heil G, Seipelt G, Hofmann W, Fischer JT, Langer W, et al. Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk acute myeloid leukemia (AML). Ann Hematol. 2000;79:30–35
  85. de Witte TM, Suciu S, Peetermans M, Fenaux P, Strijckmans P, Hayat M, et al. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration (A pilot study by the Leukemia Cooperative Group of the European Organisationi for Research and Treatment in Cancer (EORTC-LCG)). Leukemia. 1995;9:1805–1811
  86. Agrawal S, Unterberg M, Koschmieder S, zur Stadt U, Brunnberg U, Verbeek W, et al. DNA methylation of tumor suppressor genes in clinical remission predicts the relapse risk in acute myeloid leukemia. Cancer Res. 2007;67:1370–1377
  87. Jones PA, Taylor SM. Cellular differentiation, cytidine analogs and DNA methylation. Cell. 1980;20:85–93
  88. Baylin SB. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol. 2005;2:S4–S11(suppl 1).
  89. Glover AB, Leyland-Jones BR, Chun HG, Davies B, Hoth DF. Azacitidine: 10 years later. Cancer Treat Rep. 1987;71:737–746
  90. Silverman LR, Holland JF, Weinberg RS, Alter BP, Davis RB, Ellison RR, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitor hematopoiesis in patienst with myelodysplastic syndromes. Leukemia. 1993;7:21–29
  91. Silverman LHJ, Demakos E, et al. Azacitidine in myelodysplastic syndromes: CALGB studies 8421 and 8921. Ann Hematol. 1994;68:A12
  92. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissiq R, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429–2440
  93. Kornblith AB, Herndon JE, Silverman LR, Demakos EP, Odchimar-Reissig R, Holland JF, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002;20:2441–2452
  94. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895–3903
  95. Marcucci G, Silverman L, Eller M, Lintz L, Beach CL. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol. 2005;45:597–602
  96. Lyons RM, Cosgriff T, Modi S, McIntyre H, Fernando I, Backstrom J, et al. Results of the initial treatment phase of a study of three alternative dosing schedules of azacitidine (Vidaza(R)) in patients with myelodysplastic syndromes (MDS). ASH Annual Meeting Abstr. 2007;110:819
  97. Fenaux P, Mufti GJ, Santini V, Finelli C, Giagounidis A, et al. Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional care regimens (CCR): results of the AZA-001 Phase III study. ASH Annual Meeting Abstr. 2007;110:817
  98. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–425
  99. List AF, Fenaux P, Mufti GJ, Hellström-Lindberg E, Gore S, Bennett JM, et al. Effect of azacitidine on overall survival in higher-risk myelodysplastic syndromes without complete remission. J Clin Oncol. 2008;26:7006
  100. Karon M, Sieger L, Leimbrock S, Finklestein JZ, Nesbit ME, Swaney JJ. 5-Azacytidine: a new active agent for the treatment of acute leukemia. Blood. 1973;42:359–365
  101. Kalwinsky DK, Dahl GV, Mirro J, Jackson CW, Look AT. Induction failures in childhood acute nonlymphocytic leukemia: etoposide/5-azacytidine for cases refractory to daunorubicin/cytarabine. Med Pediatr Oncol. 1986;14:245–250
  102. Steuber CP, Krischer J, Holbrook T, Camitta B, Land V, Sexauer C, et al. Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study. J Clin Oncol. 1996;14:1521–1525
  103. Sudan N, Rossetti JM, Shadduck RK, Latsko J, Lech JA, Kaplan RB, et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer. 2006;107:1839–1843
  104. Al-Ali HK, Schwind S, Becker C, Mueller C, Niederwieser D. 5-Azacitidine induces hematologic responses in a high proportion of patients with acute myeloid leukaemia refractory to or not eligible for intensive chemotherapy. ASH Annual Meeting Abstr. 2006;108:1953
  105. Goldberg SL, Hsu JW, Orr AR, Rowley SD, Donato ML, McKiernan P, et al. 5-Azacitidine therapy in elderly patients with acute myelogenous leukemia yields similar survival compared to 3+7 induction chemotherapy with less transfusional support, bacteremias, and hospital days. ASH Annual Meeting Abstr. 2006;108:4569
  106. Nand S, Godwin J, Smith S, Barton K, Germano E, Stiff P. Azacitidine plus gemtuzumab ozogamicin (GO): a novel combination in the treatment of acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS) in the elderly. ASH Annual Meeting Abstr. 2006;108:1981
  107. Quagliana JM, O'Bryan RM, Baker L, Gottlieb J, Morrison FS, Eyre HJ, et al. Phase II study of 5-azacytidine in solid tumors. Cancer Treat Rep. 1977;61:51–54
  108. Weiss AJ, Metter GE, Nealon TF, Keanan JP, Ramirez G, Swaiminathan A, et al. Phase II study of 5-azacytidine in solid tumors. Cancer Treat Rep. 1977;61:55–58
  109. Bast RCLR, Hu W. A phase IIa study of a sequential regimen using azacitidine to reverse platinum resistance to carboplatin in patients with platinum resistant or refractory epithelial ovarian cancer. J Clin Oncol. 2008;26:3500
  110. Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, et al. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res. 1998;58:5310–5314
  111. Sonpavde GAA, Delaune R, Garbo LE, Rousey RE, Weinstein RE, et al. Azacitidine for castration-resistant prostate cancer progressing on combined androgen blockade. J Clin Oncol. 2008;26:5172
  112. de Vos D, van Overveld W. Decitabine: a historical review of the development of an epigenetic drug. Ann Hematol. 2005;84(suppl 1):3–8
  113. Pliml JSF. Synthesis of 2′-deoxy-D-ribofuranosyl-5-azacytosine. Coll Czeck Chem Commun. 1964;29:2576–2577
  114. Wijermans PW, Krulder JW, Huijgens PC, Neve P. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia. 1997;11:1–5
  115. Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000;18:956–962
  116. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood. 2004;103:1635–1640
  117. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109:52–57
  118. Ruter B, Wijermans PW, Lubbert M. Superiority of prolonged low-dose azanucleoside administration? (Results of 5-aza-2′-deoxycytidine retreatment in high-risk myelodysplasia patients). Cancer. 2006;106:1744–1750
  119. Borthakur G, Ahdab SE, Ravandi F, Faderl S, Ferrajoli A, Newman B, et al. Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine. Leuk Lymphoma. 2008;49:690–695
  120. Momparler RL, Rivard GE, Gyger M. Clinical trial on 5-AZA-2′-deoxycytidine in patients with acute leukemia. Pharmacol Ther. 1985;30:277–286
  121. Ravandi F, Kantarjian H, Cohen A, Davis M, O'Brien S, Anderlini P, et al. Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant. 2001;27:1221–1225
  122. de Lima M, Ravandi F, Shahjahan M, Andersson B, Couriel D, Donato M, et al. Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias. Cancer. 2003;97:1242–1247
  123. Kantarjian HM, O'Brien SM, Keating M, Bennett JM, Albitar M, DiPersio J, et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia. 1997;11:1617–1620
  124. Kantarjian HM, O'Brien S, Cortes J, Giles FJ, Faderl S, Issa JP, et al. Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer. 2003;98:522–528
  125. Issa J-PJ, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol. 2005;23:3948–3956
  126. La Rosee P, Johnson K, Corbin AS, Stoffregen EP, Moseson EM, Willis S, et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood. 2004;103:208–215
  127. Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'Brien S, Verstovsek S, et al. Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer. 2007;109:899–906
  128. van Groeningen CJ, Leyva A, O'Brien AMP, Gall HE, Pinedo HM. Phase I and pharmacokinetic study of 5-Aza-2′-deoxycytidine (NSC 127716) in cancer patients. Cancer Res. 1986;46:4831–4836
  129. Abele R, Clavel M, Dodion P, Bruntsch U, Gundersen S, Smyth J, et al. The EORTC Early Clinical Trials Cooperative Group experience with 5-aza-2′-deoxycytidine (NSC 127716) in patients with colo-rectal, head and neck, renal carcinomas and malignant melanomas. Eur J Cancer Clin Oncol. 1987;23:1921–1924
  130. Clavel M, Monfardini S, Fossa S, Smyth J, Renard J, Kaye SB. 5-Aza-2′-deoxycytidine (NSC 127716) in non-seminomatous testicular cancer (Phase II from the EORTC Early Clinical Trials Cooperative Group and Genito-Urinary Group). Ann Oncol. 1992;3:399–400
  131. Sessa C, ten Bokkel Huinink W, Stoter G, Renard J, Cavalli F. Phase II study of 5-aza-2′-deoxycytidine in advanced ovarian carcinoma (The EORTC Early Clinical Trials Group). Eur J Cancer. 1990;26:137–138
  132. Thibault A, Figg WD, Bergan RC, Lush RM, Myers CE, Tompkins A, et al. A phase II study of 5-aza-2′deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer. Tumori. 1998;84:87–89
  133. Momparler RL, Bouffard DY, Momparler LF, Dionne J, Belanger K, Ayoub J. Pilot phase I-II study on 5-aza-2′-deoxycytidine (Decitabine) in patients with metastatic lung cancer. Anticancer Drugs. 1997;8:358–368
  134. Abbruzzese JL, Frost P. Studies on the mechanism of the synergistic interaction between 2′-deoxy-5-azacytidine and cisplatin. Cancer Chemother Pharmacol. 1992;30:31–36
  135. Lenzi R, Frost P, Abbruzzese JL. Modulation of cisplatin resistance by 2′-deoxy-5-azacytidine in human ovarian tumor cell lines. Anticancer Res. 1994;14:247–251
  136. Schwartsmann G, Schunemann H, Gorini CN, Filho AF, Garbino C, Sabini G, et al. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs. 2000;18:83–91
  137. Aparicio A, Eads CA, Leong LA, Laird PW, Newman EM, Synold TW, et al. Phase I trial of continuous infusion 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol. 2003;51:231–239
  138. Samlowski WE, Leachman SA, Wade M, Cassidy P, Porter-Gill P, Busby L, et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol. 2005;23:3897–3905
  139. Schrump DS, Fischette MR, Nguyen DM, Zhao M, Li X, Kunst TF, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res. 2006;12:5777–5785
  140. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, et al. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med. 1995;1:686–692
  141. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, et al. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med. 1998;187:1349–1354
  142. Tureci O, Mack U, Luxemburger U, Heinen H, Krummenauer F, Sester M, et al. Humoral immune responses of lung cancer patients against tumor antigen NY-ESO-1. Cancer Lett. 2006;236:64–71
  143. Driscoll JS, Marquez VE, Plowman J, Liu PS, Kelley JA, Barchi JJ. Antitumor properties of 2(1H)-pyrimidinone riboside (zebularine) and its fluorinated analogues. J Med Chem. 1991;34:3280–3284
  144. McCormack PL, Palmer DG. Sulphydryl dependence of the inhibition of mitogen-induced human lymphocyte proliferation by sodium aurothiomalate. Biochem Pharmacol. 1980;29:3333–3336
  145. Cheng JC, Matsen CB, Gonzales FA, Ye W, Greer S, Marquez VE, et al. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst. 2003;95:399–409
  146. Yoo CB, Chuang JC, Byun H-M, Egger G, Yang AS, Dubeau L, et al. Long-term epigenetic therapy with oral zebularine has minimal side effects and prevents intestinal tumors in mice. Cancer Prev Res 2008:1940-6207.CAPR-1907-0008.
  147. Holleran JL, Parise RA, Joseph E, Eiseman JL, Covey JM, Glaze ER, et al. Plasma pharmacokinetics, oral bioavailability, and interspecies scaling of the DNA methyltransferase inhibitor, zebularine. Clin Cancer Res. 2005;11:3862–3868
  148. Newman EM, Santi DV. Metabolism and mechanism of action of 5-fluorodeoxycytidine. Proc Natl Acad Sci U S A. 1982;79:6419–6423
  149. Kaysen J, Spriggs D, Kufe D. Incorporation of 5-fluorodeoxycytidine and metabolites into nucleic acids of human MCF-7 breast carcinoma cells. Cancer Res. 1986;46:4534–4538
  150. Beumer JH, Parise RA, Newman EM, Doroshow JH, Synold TW, Lenz HJ, et al. Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Cancer Chemother Pharmacol. 2008;62:363–368
  151. Byun HM, Choi SH, Laird PW, Trinh B, Siddiqui MA, Marquez VE, et al. 2′-Deoxy-N4-[2-(4-nitrophenyl)ethoxycarbonyl]-5-azacytidine: a novel inhibitor of DNA methyltransferase that requires activation by human carboxylesterase 1. Cancer Lett. 2008;266:238–248
  152. Brueckner B, Garcia Boy R, Siedlecki P, Musch T, Kliem HC, Zielenkiewicz P, et al. Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. Cancer Res. 2005;65:6305–6311
  153. Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res. 2006;66:2794–2800
  154. Cornacchia E, Golbus J, Maybaum J, Strahler J, Hanash S, Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol. 1988;140:2197–2200
  155. Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H, et al. Tea polyphenol (-)-epigallocatechin-3-Gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003;63:7563–7570
  156. Chuang JC, Yoo CB, Kwan JM, Li TWH, Liang G, Yang AS, et al. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine. Mol Cancer Ther. 2005;4:1515–1520
  157. Momparler RL. Cancer epigenetics. Oncogene 22:6479-83.
  158. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002;16:6–21
  159. Bird AP, Wolffe AP. Methylation-induced repression– belts, braces, and chromatin. Cell. 1999;99:451–454
  160. Fahrner JA, Eguchi S, Herman JG, Baylin SB. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res. 2002;62:7213–7218
  161. Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293:1074–1080
  162. Jones PL, Jan Veenstra GC, Wade PA, et al. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet. 1998;19:187–191
  163. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet. 1999;21:103–107
  164. Gagnon J, Shaker S, Primeau M, Hurtubise A, Momparler RL. Interaction of 5-aza-2′-deoxycytidine and depsipeptide on antineoplastic activity and activation of 14-3-3sigma, E-cadherin and tissue inhibitor of metalloproteinase 3 expression in human breast carcinoma cells. Anticancer Drugs. 2003;14:193–202
  165. Primeau M, Gagnon J, Momparler RL. Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2prime-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int J Cancer. 2003;103:177–184
  166. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006;66:6361–6369
  167. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 2001;20:6969–6978
  168. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem. 2001;276:36734–36741
  169. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108:3271–3279
  170. Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, et al. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol. 2007;25:3884–3891
  171. Garcia-Manero G, Yang H, Bueso-Ramos C, Ferrajoli A, Cortes J, Wierda WG, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood. 2008;111:1060–1066
  172. Weiser TS, Guo ZS, Ohnmacht GA, Parkhurst ML, Tong-On P, Marincola FM, et al. Sequential 5-aza-2′-deoxycytidine-depsipeptide FR901228 treatment induces apoptosis preferentially in cancer cells and facilitates their recognition by cytolytic T lymphocytes specific for NY-ESO-1. J Immunother. 2001;24:151–161
  173. Silverman LR, Verma A, Odchimar-Reissig R, Cozza A, Najfeld V, Licht JD. A phase I/II study of vorinostat, an oral histone deacetylase inhibitor, in combination with azacitidine in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) (Initial results of the phase I trial: A New York Cancer Consortium). J Clin Oncol. 2008;26:7000
  174. Yee KWL, Minden MD, Brandwein J, Schimmer A, Schuh A, Gupta V, et al. A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia (AML). ASH Annual Meeting Abstr. 2007;110:908
  175. Lin J, Yao D-m, Qian J, Wang Y-l, Han L-x, Jiang Y-w, et al. Methylation status of fragile histidine triad (FHIT) gene and its clinical impact on prognosis of patients with myelodysplastic syndrome. Leuk Res. 2008;32:1541–1545
  176. Wu Q, Lothe R, Ahlquist T, Silins I, Trope C, Micci F, et al. DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer. 2007;6:45
  177. Johan MF, Bowen DT, Frew ME, Goodeve AC, Reilly JT. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol. 2005;129:60–65
  178. Ihalainen JPS, Savolainen ER, Janssen SE, Palotie A. Hypermethylation of the calcitonin gene in the myelodysplastic syndromes. Leukemia. 1993;7:263–267
  179. Jost E, Schmid J, Wilop S, Schubert C, Suzuki H, Herman JG, et al. Epigenetic inactivation of secreted Frizzled-related proteins in acute myeloid leukaemia. Br J Haematol 2008 [Epub ahead of print].
  180. Kroeger H, Jelinek J, Estecio MRH, He R, Kondo K, Chung W, et al. Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood. 2008;112:1366–1373
  181. Hess CJ, Errami A, Berkhof J, Denkers F, Ossenkoppele GJ, Nygren AOH, et al. Concurrent methylation of promoters from tumor associated genes predicts outcome in acute myeloid leukemia. Leuk Lymphoma. 2008;49:1132–1141
  182. Schmelz K, Wagner M, Dorken B, Tamm I. 5-Aza-2′-deoxycytidine induces p21WAF expression by demethylation of p73 leading to p53-independent apoptosis in myeloid leukemia. Int J Cancer. 2005;114:683–695
  183. Oka T, Ouchida M, Koyama M, Oka T, Ouchida M, Koyama M, et al. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res. 2002;62:6390–6394
  184. Hoshino K, Quintas-Cardama A, Yang H, Sanchez-Gonzalez B, Garcia-Manero G. Aberrant DNA methylation of the Src kinase Hck, but not of Lyn, in Philadelphia chromosome negative acute lymphocytic leukemia. Leukemia. 2007;21:906–911
  185. Agirre X, Roman-Gomez J, Vazquez I, Jimenez-Velasco A, Garate L, Montiel-Duarte C, et al. Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia. Int J Cancer. 2006;118:1945–1953
  186. Liu TC, Lin SF, Chang JG, Yang MY, Hung SY, Chang CS. Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. Br J Haematol. 2003;123:654–661
  187. Nagy E, Beck Z, Kiss A, et al. Frequent methylation of p16INK4A and p14ARF genes implicated in the evolution of chronic myeloid leukaemia from its chronic to accelerated phase. Eur J Cancer. 2003;39:2298–2305
  188. Roman-Gomez J, Castillejo JA, Jimenez A, Cervantes F, Boque C, Hermosin L, et al. Cadherin-13, a mediator of calcium-dependent cell-cell adhesion, is silenced by methylation in chronic myeloid leukemia and correlates with pretreatment risk profile and cytogenetic response to interferon. Alfa J Clin Oncol. 2003;21:1472–1479
  189. Yang M-Y, Liu T-C, Chang J-G, Lin P-M, Lin S-F. JunB gene expression is inactivated by methylation in chronic myeloid leukemia. Blood. 2003;101:3205–3211
  190. Oka T, Ouchida M, Koyama M, Ogama Y, Takada S, Nakatani Y, et al. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res. 2002;62:6390–6394
  191. Shteper PJ, Siegfried Z, Asimakopoulos FA, Palumbo GA, Rachmilewitz EA, Ben-Neriah Y, et al. ABL1 methylation in Ph-positive ALL is exclusively associated with the P210 form of BCR-ABL. Leukemia. 2001;15:575–582
  192. Strathdee G, Holyoake TL, Sim A, Parker A, Oscier DG, Melo JV, et al. Inactivation of HOXA genes by hypermethylation in myeloid and lymphoid malignancy is frequent and associated with poor prognosis. Clin Cancer Res. 2007;13:5048–5055
  193. Papageorgiou SG, Lambropoulos S, Pappa V, Economopoulou C, Kontsioti F, Papageorgiou E, et al. Hypermethylation of the p15INK4B gene promoter in B-chronic lymphocytic leukemia. Am J Hematol. 2007;82:824–825
  194. Motiwala T, Majumder S, Kutay H, Smith DS, Neuberg DS, Lucas DM, et al. Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia. Clin Cancer Res. 2007;13:3174–3181
  195. Raval A, Tanner SM, Byrd JC, Perko JD, Chen S-S, et al. Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell. 2007;129:879–890
  196. Petrocca F, Iliopoulos D, Qin HR, Nicoloso MS, Yendamuri S, Wojcik SE, et al. Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. Cancer Res. 2006;66:10287–10291
  197. Strathdee G, Sim A, Parker A, Oscier D, Brown R. Promoter hypermethylation silences expression of the HoxA4 gene and correlates with IgVh mutational status in CLL. Leukemia. 2006;20:1326–1329
  198. Raval A, Lucas DM, Matkovic JJ, Bennett KL, Liyanarachchi S, Young DC, et al. TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol. 2005;23:3877–3885
  199. Bechter OE, Eisterer W, Dlaska M, Kühr T, Thaler J. CpG island methylation of the hTERT promoter is associated with lower telomerase activity in B-cell lymphocytic leukemia. Exp Hematol. 2002;30:26–33
  200. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;92:564–569
  201. Esteller M, Fraga MF, Guo M, Garcia-Foncillas J, Hedenfalk I, Godwin AK, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet. 2001;10:3001–3007
  202. Watanabe Y, Ueda H, Etoh T, Koike E, Fujinami N, Mitsuhashi A, et al. A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer. Anticancer Res. 2007;27:1449–1452
  203. Wiley A, Katsaros D, Chen H, Rigault de la Longrais IA, Beeghly A, Puopolo M, et al. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer. 2006;107:299–308
  204. Choi YL, Kang SY, Shin YK, Choi JS, Kim SH, Lee SJ, et al. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas. Virchows Arch. 2006;448:331–336
  205. Makarla PB, Saboorian MH, Ashfaq R, Toyooka KO, Toyooka S, Minna JD, et al. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res. 2005;11:5365–5369
  206. Petrocca F, Iliopoulos D, Qin HR, et al. Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. Cancer Res. 2006;66:10287–10291
  207. Cooper WN, Dickinson RE, Dallol A, Grigorieva EV, Pavlova TV, Hesson LB, et al. Epigenetic regulation of the ras effector//tumour suppressor RASSF2 in breast and lung cancer. Oncogene. 2007;27:1805–1811
  208. Toyooka KO, Toyooka S, Virmani AK, Sathyanarayana UG, Euhus DM, Gilcrease M, et al. Loss of expression and aberrant methylation of the CDH13 (H-Cadherin) gene in breast and lung carcinomas. Cancer Res. 2001;61:4556–4560
  209. Toyooka S, Toyooka KO, Maruyama R, Virmani AK, Girard L, Miyajima K, et al. DNA methylation profiles of lung tumors. Mol Cancer Ther. 2001;1:61–67
  210. Machida EO, Brock MV, Hooker CM, Nakayama J, Ishida A, Amano J, et al. Hypermethylation of ASC/TMS1 is a sputum marker for late-stage lung cancer. Cancer Res. 2006;66:6210–6218
  211. Brock MV, Kim MP, Hooker CM, Alberg AJ, Jordan MM, Roig CM, et al. Pulmonary resection in octogenarians with stage I nonsmall cell lung cancer: a 22-year experience. Ann Thorac Surg. 2004;77:271–277
  212. Herman JG, Merlo A, Mao L, Lapidus RG, Issa J-PJ, Davidson NE, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res. 1995;55:4525–4530
  213. Vousden KH. p53: Death Star. Cell. 2000;103:691–694
  214. Rhee I, Bachman KE, Park BH, Jair K-W, Yen R-WC, Schuebel KE, et al. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002;416:552–556
  215. Gazzoli I, Loda M, Garber J, Syngal S, Kolodner RD. A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. Cancer Res. 2002;62:3925–3928
  216. Shen L, Kondo Y, Hamilton SR, Rashid A, Issa J-PJ. p14 methylation in human colon cancer is associated with microsatellite instability and wild-type p53. Gastroenterology. 2003;124:626–633
  217. Whitehall VLJ, Walsh MD, Young J, Leggett BA, Jass JR. Methylation of O-6-methylguanine DNA methyltransferase characterizes a subset of colorectal cancer with low-level DNA microsatellite instability. Cancer Res. 2001;61:827–830
  218. Noetzel E, Veeck J, Niederacher D, Galm O, Horn F, Hartmann A, et al. Promoter methylation-associated loss of ID4 expression is a marker of tumour recurrence in human breast cancer. BMC Cancer. 2008;8:154
  219. Herman JG, Merlo A, Mao L, Lapidus RG, Issa J-PJ, Davidson NE, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. 1995;55:4525-30.
  220. Droufakou S, Deshmane V, Roylance R, Hanby A, Tomlinson I, Hart IR. Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. Int J Cancer. 2001;92:404–408
  221. Sarrio D, Moreno-Bueno G, Hardisson D, Sanchez-Estevez C, Guo M, Herman JG, et al. Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. Int J Cancer. 2003;106:208–215
  222. Munot K, Bell SM, Lane S, Horgan K, Hanby AM, Speirs V. Pattern of expression of genes linked to epigenetic silencing in human breast cancer. Hum Pathol. 2006;37:989–999
  223. Xu XL, Yu J, Zhang HY, Sun MH, Gu J, Du X, et al. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol. 2004;10:3441–3454
  224. Stearns V, Zhou Q, Davidson NE. Epigenetic regulation as a new target for breast cancer therapy. Cancer Invest. 2007;25:659–665
  225. Lee WH, Morton RA, Epstein JI, Brooks JD, Campbell PA, Bova GS, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci U S A. 1994;91:11733–11737
  226. Hu J-F, Nguyen PH, Pham NV, Vu TH, Hoffman AR. Modulation of Igf2 genomic imprinting in mice induced by 5-azacytidine, an inhibitor of DNA methylation. Mol Endocrinol. 1997;11:1891–1898
  227. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, et al. Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res. 2004;64:1975–1986
  228. Fu VX, Schwarze SR, Kenowski ML, LeBlanc S, Svaren J, Jarrard DF. A loss of insulin-like growth factor-2 imprinting is modulated by CCCTC-binding factor down-regulation at senescence in human epithelial cells. J Biol Chem. 2004;279:52218–52226
  229. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A. 1994;91:9700–9704
  230. Kagara I, Enokida H, Kawakami K, Matsuda R, Toki K, Nishimura H, et al. CpG hypermethylation of the UCHL1 Gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma. J Urol. 2008;180:343–351
  231. Kvasha S, Gordiyuk V, Kondratov A, Ugryn D, Zgonnyk YM, Rynditch AV, et al. Hypermethylation of the 5′CpG island of the FHIT gene in clear cell renal carcinomas. Cancer Lett. 2008;265:250–257
  232. Christoph F, Weikert S, Kempkensteffen C, Krause H, Schostak M, Kollermann J, et al. Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications. Clin Cancer Res. 2006;12:5040–5046
  233. Gumz ML, Zou H, Kreinest PA, Childs AC, Belmonte LS, LeGrand SN, et al. Secreted frizzled-related protein 1 loss contributes to tumor phenotype of clear cell renal cell carcinoma. Clin Cancer Res. 2007;13:4740–4749
  234. Costa V, Henrique R, Ribeiro F, Pinto M, Oliveira J, Lobo F, et al. Quantitative promoter methylation analysis of multiple cancer-related genes in renal cell tumors. BMC Cancer. 2007;7:133
  235. Christoph F, Hinz S, Kempkensteffen C, Schostak M, Schrader M, Miller K. mRNA expression profiles of methylated APAF-1 and DAPK-1 tumor suppressor genes uncover clear cell renal cell carcinomas with aggressive phenotype. J Urol. 2007;178:2655–2659
  236. Zhang Q, Ying J, Zhang K, Li H, Ng KM, Zhao Y, et al. Aberrant methylation of the 8p22 tumor suppressor gene DLC1 in renal cell carcinoma. Cancer Lett. 2007;249:220–226
  237. Okuda H, Toyota M, Ishida W, Furihata M, Tsuchiya M, Kamada M, et al. Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma. Oncogene. 2005;25:1733–1742
  238. Fukushima N, Sato N, Ueki T, Su GH, Hruban RH, Goggins M. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol. 2002;160:1573–1581
  239. Dammann R, Schagdarsurengin U, Liu L, Otto N, Gimm O, Dralle H, et al. Frequent RASSF1A promoter hypermethylation and K-ras mutations in pancreatic carcinoma. Oncogene 22:3806-12.
  240. Matsubayashi H, Sato N, Fukushima N, Yeo CJ, Walter KM, Brune K, et al. Methylation of cyclin D2 is observed frequently in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissues. Clin Cancer Res. 2003;9:1446–1452
  241. Fukushima N, Sato N, Sahin F, Su GH, Hruban RH, Goggins M. Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br J Cancer. 2003;89:338–343
  242. Ueki T, Toyota M, Sohn T, Yeo CJ, Issa J-PJ, Hruban RH, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res. 2000;60:1835–1839
  243. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. 2000;92:564-9.
  244. Winter JM, Ting AH, Vilardell F, Gallmeier E, Baylin SB, Hruban RH, et al. Absence of E-cadherin expression distinguishes noncohesive from cohesive pancreatic cancer. Clin Cancer Res. 2008;14:412–418
  245. Dansranjavin T, Mobius C, Tannapfel A, Bartels M, Wittekind C, Hauss J, et al. E-cadherin and DAP kinase in pancreatic adenocarcinoma and corresponding lymph node metastases. Oncol Rep. 2006;15:1125–1131
  246. Kang GH, Lee S, Kim JS, Jung HY. Profile of aberrant CpG island methylation along the multistep pathway of gastric carcinogenesis. Lab Invest. 2003;83:635–641
  247. To KF, Leung WK, Lee TL, Yu J, Tong JH, Chan MW, et al. Promoter hypermethylation of tumor-related genes in gastric intestinal metaplasia of patients with and without gastric cancer. Int J Cancer. 2002;102:623–628
  248. Seidel C, Bartel F, Rastetter M, Bluemke K, Wurl P, Taubert H, et al. Alterations of cancer-related genes in soft tissue sarcomas: hypermethylation of RASSF1A is frequently detected in leiomyosarcoma and associated with poor prognosis in sarcoma. Int J Cancer. 2005;114:442–447
  249. Kawaguchi K-i, Oda Y, Saito T, Yamamoto H, Takahira T, Kobayashi C, et al. DNA hypermethylation status of multiple genes in soft tissue sarcomas. Mod Pathol. 2005;19:106–114
  250. Seidel C, Schagdarsurengin U, Blumke K, Wurl P, Pfeifer GP, Hauptmann S, et al. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog. 2007;46:865–871
  251. Spugnardi M, Tommasi S, Dammann R, Pfeifer GP, Hoon DSB. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma. Cancer Res. 2003;63:1639–1643
  252. Hoon DSB, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene. 2004;23:4014–4022
  253. Worm J, Christensen C, Gronbaek K, Tulchinsky E, Guldberg P. Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene. 2004;23:5215–5226
  254. Fischer JR, Ohnmacht U, Rieger N, Zemaitis M, Stoffregen C, Kostrzewa M, et al. Promoter methylation of RASSF1A (RAR[beta] and DAPK predict poor prognosis of patients with malignant mesothelioma). Lung Cancer. 2006;54:109–116
  255. Tsou JA, Shen LYC, Siegmund KD, Long TI, Laird PW, Seneviratne CK, et al. Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. Lung Cancer. 2005;47:193–204
  256. Hirao T, Bueno R, Chen C-J, Gordon GJ, Heilig E, Kelsey KT. Alterations of the p16INK4 locus in human malignant mesothelial tumors. Carcinogenesis. 2002;23:1127–1130

PII: S0147-0272(08)00044-5

doi: 10.1016/j.currproblcancer.2008.08.002

Current Problems in Cancer
Volume 32, Issue 5 , Pages 187-235 , September 2008

Article Tools